Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
307.92
-0.21 (-0.07%)
Dec 15, 2025, 4:00 PM EST - Market closed
Bio-Rad Laboratories Market Cap
Bio-Rad Laboratories has a market cap or net worth of $8.31 billion as of December 15, 2025. Its market cap has decreased by -12.15% in one year.
Market Cap
8.31B
Enterprise Value
8.28B
1-Year Change
-12.15%
Ranking
Category
Stock Price
$307.92
Market Cap Chart
Since December 1, 1998, Bio-Rad Laboratories's market cap has increased from $261.00M to $8.31B, an increase of 3,082.41%. That is a compound annual growth rate of 13.65%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 12, 2025 | 8.31B | -9.63% |
| Dec 31, 2024 | 9.20B | -2.27% |
| Dec 29, 2023 | 9.41B | -24.96% |
| Dec 30, 2022 | 12.54B | -44.52% |
| Dec 31, 2021 | 22.61B | 29.99% |
| Dec 31, 2020 | 17.39B | 56.99% |
| Dec 31, 2019 | 11.08B | 59.20% |
| Dec 31, 2018 | 6.96B | -2.05% |
| Dec 29, 2017 | 7.10B | 31.92% |
| Dec 30, 2016 | 5.38B | 32.52% |
| Dec 31, 2015 | 4.06B | 16.39% |
| Dec 31, 2014 | 3.49B | -1.57% |
| Dec 31, 2013 | 3.55B | 19.03% |
| Dec 31, 2012 | 2.98B | 10.33% |
| Dec 30, 2011 | 2.70B | -6.45% |
| Dec 31, 2010 | 2.89B | 8.90% |
| Dec 31, 2009 | 2.65B | 28.98% |
| Dec 31, 2008 | 2.06B | -26.11% |
| Dec 31, 2007 | 2.78B | 27.31% |
| Dec 29, 2006 | 2.18B | 27.59% |
| Dec 30, 2005 | 1.71B | 15.63% |
| Dec 31, 2004 | 1.48B | 0.60% |
| Dec 31, 2003 | 1.47B | 50.86% |
| Dec 31, 2002 | 975.80M | 23.39% |
| Dec 31, 2001 | 790.80M | 99.29% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 920.02B |
| Johnson & Johnson | 509.76B |
| AbbVie | 394.69B |
| UnitedHealth Group | 309.65B |
| AstraZeneca | 278.45B |
| Novartis AG | 254.39B |
| Merck & Co. | 248.95B |
| Novo Nordisk | 224.22B |